Michelle Griffin

Michelle R.
Griffin is an Independent Director at Adaptive Biotechnologies Corp.
since 2019.
Former roles include Independent Director at Acer Therapeutics, Inc. (2017–2023) and Chinook Therapeutics, Inc. (2020–2023); Chairman at Universal Cells, Inc. (2017–2018); Director at Sonus Pharmaceuticals, Inc. (2004–2008), Virginia Mason Medical Center (2014–2018), Virginia Mason Health System (2014–2018), PhaseRx, Inc. (2016–2018), Polynoma LLC (2012–2014), and Opexa Therapeutics, Inc.; Independent Director at HTG Molecular Diagnostics, Inc.; Director at Corixa Corp.
(2014–2017); Controller at Corixa Corp.
(2014–2017); Chief Financial Officer & Senior Vice President at Dendreon Corp.
(2005–2006); Chief Executive & Operating Officer, Senior VP at Emergent Product Development Seattle (2009–2010); Chief Operating Officer & Senior Vice President at Emergent Product Development Seattle (2011–2013); Chief Financial Officer & Executive VP-Operations at OncoGenex Pharmaceuticals, Inc. (2011–2013); Chief Financial Officer at Corixa Corp.
(1997–2005); Principal at Pacific Biotechnology Consulting Group (2013–2020).
Education includes undergraduate studies at George Mason University and an MBA from Seattle University.